Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...2425262728293031323334...4748»
  • ||||||||||  Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus, Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
    A phase Ⅱ study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_978;    
    P2
    Conclusions In this phase 2 study, patients with ES-SCLC who continued toripalimab with anlotinib as maintenance therapy after induction therapy with etoposide-platinum chemotherapy showed promising anti-tumor activity and tolerable toxicities. Trial Registration Clinical trial information: NCT04363255.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, cadonilimab (AK104) / Akesobio
    Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_350;    
    P1/2, P2
    Conclusions Cadonilimab, an IgG1 antibody with Fc-engineering, exhibits neither Fc effector functions including ADCC, ADCP, CDC, nor activating macrophage to secret IL-6 or IL-8. Possible tumor tissue preferential retention of Cadonilimab over conventional anti-PD-1 and anti-CTLA-4 antibodies noted above could potentially lead to better safety profile.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Metastases:  First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer (clinicaltrials.gov) -  Sep 30, 2021   
    P2,  N=172, Recruiting, 
    Possible tumor tissue preferential retention of Cadonilimab over conventional anti-PD-1 and anti-CTLA-4 antibodies noted above could potentially lead to better safety profile. Not yet recruiting --> Recruiting
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Metastases:  Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer (clinicaltrials.gov) -  Sep 27, 2021   
    P2,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=60 --> 0 | Initiation date: Nov 2020 --> Nov 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2021 --> Dec 2023
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. (Pubmed Central) -  Sep 19, 2021   
    In addition, anlotinib also displays strong cytotoxicity against bortezomib-resistant MM cells. Our study demonstrates the extraordinary anti-MM effect of anlotinib both in vitro and in vivo, which provides solid evidence and a promising rationale for future clinical application of anlotinib in the treatment of human MM.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Retrospective data, Journal:  Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis. (Pubmed Central) -  Sep 15, 2021   
    In the future, anlotinib combined with an Nrf2 inhibitor may provide a new therapeutic strategy for the treatment of human PC. This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date, Metastases:  Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma (clinicaltrials.gov) -  Sep 14, 2021   
    P2,  N=20, Completed, 
    This meta-analysis will provide clinical evidence of anlotinib-containing regimens for advanced SCLC, which may or may not be found for anlotinib use. Recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2021
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Trial completion date, Trial primary completion date:  Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) -  Sep 2, 2021   
    P2,  N=120, Recruiting, 
    These differences may be due to their different sensitivities to targets such as RET, warranting further study. Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Focus V (anlotinib) / Advenchen, Sino Biopharm
    New P2 trial, Metastases:  TAS-102 and Anlotinib in ?3 Lines mGC (clinicaltrials.gov) -  Aug 30, 2021   
    P2,  N=45, Recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) -  Aug 30, 2021   
    P2,  N=38, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2020 --> Nov 2020 | Trial primary completion date: Mar 2019 --> Sep 2020
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Clinical, Journal:  Primary cardiac angiosarcoma: a case report. (Pubmed Central) -  Aug 27, 2021   
    Angiosarcoma was verified histologically. After palliative resection of the primary tumor followed by concurrent chemoradiotherapy and targeted therapy, the patient exhibited overall survival of 23 months, highlighting the potential utility of this treatment strategy.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Retrospective data, Journal, Real-world evidence:  Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. (Pubmed Central) -  Aug 25, 2021   
    Phase classification: P2/3 --> P3 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Oct 2023 The combination of anlotinib and PD-1 inhibitor has promising efficacy and manageable toxicity as a second- or later-line treatment of relapsed NSCLC and possibly for relapsed SCLC.
  • ||||||||||  temozolomide / Generic mfg., methotrexate / Generic mfg.
    Clinical, Journal:  Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report. (Pubmed Central) -  Aug 20, 2021   
    She underwent concurrent radiotherapy and chemotherapy according to the Stupp protocol in combination with a multi-target antiangiogenic drug and additional intrathecal chemotherapy using methotrexate...The chemotherapy with temozolomide was stopped and replaced with radiotherapy combined with tumor treating fields (TTF), the poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib, and anlotinib...Considering the patient's tolerance to the treatment, the combined therapy of TTF and anlotinib was continued, and osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor with good permeability of the blood-brain barrier, was added...Head magnetic resonance imaging (plain scan + enhanced scan) suggested that the lesions were stable. For rapidly progressing glioblastomas or histological grade II/III IDHwt astrocytomas, the combination of TTF and a PARP inhibitor during radiotherapy may have a synergistic effect on tumor control and is well tolerated by patients.